Immucell (ICCC) Liabilities and Shareholders Equity (2010 - 2026)

Immucell (ICCC) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $42.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 5.69% year-over-year to $42.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $180.6 million (up 3.52% YoY) and the FY2025 annual result came in at $42.5 million, down 5.69% from the prior year.
• Liabilities and Shareholders Equity retreated to $42.5 million in Q4 2025, from $45.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $46.7 million in Q2 2025 to a low of $39.6 million in Q1 2021.
• A 5-year average of $44.3 million and a median of $44.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity gained 17.86% — and 2023, when it retreated 7.66%.
• Tracing ICCC's Liabilities and Shareholders Equity over 5 years: stood at $44.5 million in 2021, then advanced by 0.89% to $44.9 million in 2022, then fell by 2.35% to $43.8 million in 2023, then advanced by 2.95% to $45.1 million in 2024, then dropped by 5.69% to $42.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $42.5 million (Q4 2025), $45.7 million (Q3 2025), and $46.7 million (Q2 2025), per Business Quant data.